Patent · US Active

Hybrid galactoside inhibitor of galectins

US10800804B2 · kind B2 · utility

0Cited by

5References

20Claims

0Family size

Assignee

GALECTO BIOTECH AB · DK

Inventors

Hakon Leffler · Lund, SE
Ulf Nilsson · Dozwil, CH
Fredrik Zetterberg · Copenhagen, DK

Key dates

Filing date	Nov 26, 2018
Grant date	Oct 13, 2020
Priority date	—
Expiry date	Nov 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H15/26
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.